ArticleScientific reports2026
PGE2 regulates ferroptosis and osteogenesis of MC3T3-E1 cells via NOS2.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Prostaglandin E2 (PGE2) is a key inflammatory mediator in orthodontic tooth movement, yet its precise role in regulating osteogenesis remains unclear. This study investigated the mechanism by which PGE2 influences ferroptosis and osteogenesis in MC3T3-E1 cells, focusing on nitric oxide synthase 2 (NOS2). Bioinformatic analysis identified NOS2 as a core ferroptosis-related gene after orthodontic force loading. 100 ng/mL PGE2 induced sterile inflammation and ferroptosis as evidenced by upregulated expressions of IL-6, NOS2, and ACSL4 while downregulated expressions of GPX4, FTH1 detected by RT-qPCR and western blot, alongside promoted reactive oxygen species and malondialdehyde production detected by flow cytometry. Meanwhile, PGE2 inhibited osteogenesis characterized by downregulated expressions of osteogenic markers RUNX2, Osterix, OPN, OCN and diminished ALP activity and mineralization level detected by RT-qPCR, western blot, ALP staining, ARS staining, ALP activity detection and Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.